Ustekinumab for the treatment of adults with moderate to severe psoriasis

  • Technology appraisal guidance
  • TA180
  • Published: 
  • Last updated: 
Download guidance (PDF)

6 Recommendations for further research

6.1

The Committee considered that the following research would be of value:

  • Studies comparing ustekinumab and other biological therapies in head-to-head trials, both in people whose psoriasis has shown an inadequate response to the first biological therapy and in people naive to biological therapies. These studies should investigate weight–dose relationships, as far as these can be considered within the marketing authorisations.

  • Studies investigating resource use, including frequency and length of hospitalisation and associated costs.

  • The collection of data on the use of ustekinumab and other biological therapies as part of the British Association of Dermatologists' Biologics Intervention Register (BADBIR).